Security
Addex Therapeutics Ltd American Depositary Shares · ADXN
ADXNNASDAQotherCurrentCIK 1574232Updated Oct 9, 2026
ADXN price & chart
Loading TradingView…
NASDAQ:ADXN on TradingView ↗In the news
No coverage from other publishers is available.
Financials
FY 2024 · CHFSource
Source
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||
| Profit or LossCHF | -1,841,165Source | 12,878,632Source | -2,675,152Source | -7,221,252Source | -4,690,149Source | 7,055,787Source | -10,556,227Source | -20,804,213Source | -15,351,914Source |
| Additional Financial Items | |||||||||
| AdjustmentsForSharebasedPaymentsCHF | — | — | — | — | — | 502,964Source | 1,794,467Source | 3,682,073Source | 1,178,344Source |
| AdjustmentsForUndistributedProfitsOfAssociatesCHF | — | — | — | — | — | -2,177,157Source | — | — | — |
| GeneralAndAdministrativeExpenseCHF | 534,819Source | 675,276Source | 1,303,665Source | 1,531,632Source | 1,846,678Source | 2,310,970Source | 4,965,882Source | 7,299,704Source | 5,818,682Source |
| InterestPaidClassifiedAsFinancingActivitiesCHF | — | — | — | — | — | 9,219Source | 21,607Source | 48,897Source | 63,012Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCHF | — | — | — | — | — | 73,688Source | 281,793Source | 288,076Source | 309,617Source |
| ProceedsFromIssuingSharesCHF | — | — | — | — | — | — | — | — | 10,161,746Source |
income statement · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|
| Additional Financial Items | |||||||||
| ApplicableTaxRatenumber | — | — | — | — | — | — | 0.14Source | 0.14Source | 0.14Source |
| BasicEarningsLossPerShareCHF/shares | -0.02Source | 0.13Source | -0.04Source | -0.19Source | -0.14Source | 0.07Source | -0.14Source | -0.46Source | -0.45Source |
| DepreciationRightofuseAssetsCHF | — | — | — | — | — | 74,014Source | 280,593Source | 291,573Source | 320,415Source |
| DilutedEarningsLossPerShareCHF/shares | -0.02Source | 0.13Source | -0.04Source | -0.19Source | -0.14Source | 0.07Source | -0.14Source | -0.46Source | -0.45Source |
| EmployeeBenefitsExpenseCHF | 44,496Source | 67,959Source | 1,411,960Source | 1,352,084Source | 1,273,385Source | 242,591Source | 5,376,859Source | 7,053,102Source | 4,737,138Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesCHF | 1,851Source | 4,701Source | 416,947Source | 550,221Source | 260,976Source | 17,544Source | 1,520,917Source | 3,034,740Source | 946,632Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedCHF | — | 1,545Source | 10,279Source | 14,596Source | 8,046Source | — | 35,567Source | 47,283Source | 37,512Source |
| FinanceCostsCHF | -5,828Source | 864Source | 141,725Source | 129,242Source | 22,939Source | 3,547Source | 338,892Source | 313,257Source | 63,012Source |
| FinanceIncomeCHF | 3Source | -25,832Source | 13,349Source | 205Source | -160,573Source | 26,595Source | 63,964Source | 29,251Source | 217,015Source |
| GeneralAndAdministrativeExpenseCHF | 534,819Source | 675,276Source | 1,303,665Source | 1,531,632Source | 1,846,678Source | 2,310,970Source | 4,965,882Source | 7,299,704Source | 5,818,682Source |
| IncomeTaxExpenseContinuingOperationsCHF | — | — | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseCHF | 334Source | 437Source | 93Source | 7,574Source | 17,274Source | 1,609Source | 1,644Source | 25,878Source | 39,146Source |
| InterestExpenseOnLeaseLiabilitiesCHF | 495Source | 427Source | 3,735Source | 4,758Source | 5,665Source | 1,938Source | 19,963Source | 23,019Source | 23,866Source |
| OtherIncomeCHF | 36,375Source | — | 1,100Source | 3,089Source | 79,285Source | 5,940Source | 34,116Source | 22,521Source | 236,997Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansCHF | 8,059Source | 3,466Source | 68,836Source | 51,682Source | 77,064Source | -45,425Source | 235,847Source | 279,920Source | 114,353Source |
| ProfessionalFeesExpenseCHF | 320,253Source | 376,033Source | 368,927Source | 323,390Source | 642,403Source | 1,206,813Source | 1,163,839Source | 1,424,333Source | 1,379,734Source |
| ProfitLossBeforeTaxCHF | -1,958,912Source | -1,456,761Source | -2,675,152Source | -7,221,252Source | -4,690,149Source | -4,909,342Source | -10,556,227Source | -20,804,213Source | -15,351,914Source |
| ProfitLossFromOperatingActivitiesCHF | -732,898Source | -899,316Source | -2,546,776Source | -7,092,215Source | -4,506,637Source | -2,755,233Source | -10,281,299Source | -20,520,207Source | -15,505,917Source |
| ResearchAndDevelopmentExpenseCHF | 234,454Source | 339,317Source | 1,875,088Source | 5,747,026Source | 3,731,839Source | 854,305Source | 6,962,486Source | 14,665,462Source | 12,840,540Source |
| RevenueFromInterestCHF | 3Source | 1,507Source | 13,349Source | 204Source | 1,717Source | 9,165Source | 63,964Source | 29,251Source | 5,322Source |
Filing attachments
adxn-20260630xex99d1.htm · 6-K · 2026-09-28
Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month and six-month periods ended June 30, 2026 and 2025 3 Unaudited Inte…
Read attachment ↗adxn-ex99d2.htm · 6-K · 2026-09-28
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage pharmaceutical company focused on the development of a portfolio of novel orally available small molecule drug candidates. Our business comprises a pipeline of proprietary clinical and preclinical stage drug candidates that are being developed for diseases for which there are no approved therapies or where improved therapies are needed including post-stroke sens…
Read attachment ↗tm2618934d1_ex99-1.htm · 6-K · 2026-06-25
Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets 2 as of March 31, 2026 and December 31, 2025 Unaudited Interim Condensed Consolidated Statements 3 of Comprehensive Loss for the three-month periods ended March 31, 2025 and 2026 Unaudited Inter…
Read attachment ↗tm2618934d1_ex99-2.htm · 6-K · 2026-06-25
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage pharmaceutical company focused on the development of a portfolio of novel orally available small molecule drug candidates. Our business comprises a pipeline of proprietary clinical and preclinical stage drug candidates that are being developed by our partners and internally. We or our partners are developing these clinical and preclinical stage proprietary drug c…
Read attachment ↗